Navigation Links
Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:6/12/2008

BETHESDA, Md., June 12 /Xinhua-PRNewswire/ -- Chindex International, Inc. (Nasdaq: CHDX), an independent American provider of international healthcare services and Western healthcare products in the People's Republic of China, today announced results for its fiscal year end and fourth quarter ended March 31, 2008.

For the 2008 fiscal year, the Company reported total revenue of $130.1 million, an increase of 23% over the prior year, and income from continuing operations increased 80% to $8.3 million from $4.6 million in the prior year. Net income increased 34% to $3.7 million, or earnings per share of $0.32 compared to net income of $2.7 million or earnings per share of $0.29 for the year ended March 31, 2007.

For the quarter ended March 31, 2008, revenue was $34.6 million, an increase of 40% over the prior year, and income from continuing operations decreased 55% to $426,000 from $939,000 in the prior year. The net loss for the quarter ended March 31, 2008 was $2.7 million or loss per share of $0.20 compared to net income of $665,000, or earnings per share of $0.06, for the quarter ended March 31, 2007. The quarterly results were negatively impacted by certain non-routine year-end adjustments as well as the interest charge related to the conversion of a JP Morgan convertible bond.

The Company's balance sheet as of March 31, 2008 shows cash, cash equivalents and restricted cash of $80.4 million, total assets of $136.0 million, a current ratio of 4.51:1 and stockholders' equity of $87.4 million.

Roberta Lipson, President and CEO of Chindex, commented on the results: "We continue to see great opportunity for our healthcare businesses in China -- the world's fastest growing market. Our revenue growth and profitable
'/>"/>

SOURCE Chindex International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Chindex International Announces Shelf Registration, Related Strategy and Guidance
2. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
3. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008
4. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
7. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
8. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
9. MINRAD International, Inc. Announces $40.0 Million Private Placement
10. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) ... Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... seems to dominate the breast cancer monoclonal antibody ... molecule, Herceptin has been able to dominate this ... breast cancer cells become recalcitrant and relapsed condition ...
(Date:5/27/2015)... AVIV, Israel , May 27, 2015  Tikcro ... first quarter ended March 31, 2015. ... the quarter, we continued pre-clinical work to generate functional ... in an early stage, we are encouraged by the ... this field as new antibodies which modulate immune checkpoints ...
(Date:5/27/2015)... May 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for cancer, announced today that Dr. ... the Company, will be making an Industry Expert Theater ... Chicago on Saturday, May 30, 2015, ... Expert Theater in McCormick Place. Dr. Bosch ...
(Date:5/27/2015)... May 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... on the status of the Company,s Series A ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 21 shares of Series A Preferred Stock and ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3
... Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: ... press release on July 27 , and provides the corrected ... the press release, Ampio has completed the final negotiations with DMI ... file a Form 8-K with the SEC announcing the definitive agreement ...
... AVANIR Pharmaceuticals, Inc. (Nasdaq: ... Annual Canaccord Genuity Growth Conference on Tuesday, August 10th at ... at the InterContinental Hotel in Boston .  The Canaccord Genuity Growth ... and industry leaders.   , , ...
... PLYMOUTH MEETING, Pa. , Aug. 2 /PRNewswire-Asia-FirstCall/ -- BMP ... today announced,that the Company plans to release second quarter 2010 financial results on, ... , , ... a conference call at 5:00 pm ET on August 9, ...
Cached Biology Technology:CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc. 2AVANIR to Present at the Canaccord Genuity Growth Conference 2BMP Sunstone to Report Second Quarter 2010 Financial Results 2
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... (Nov. 3, 2010) -- Scientists at Weill Cornell Medical College ... prostate cancer by uncovering evidence that it is not one ... be measured and, in the future, destroyed by targeted therapy., ... by of Dr. Mark A. Rubin, the Homer T. Hirst ...
... Salk Institute for Biological Studies and Columbia University Medical ... The Leona M. and Harry B. Helmsley Charitable Trust, ... induced pluripotent stem (iPS) cells to gain new insight ... "Stem cell research is of immense importance to ...
... plants can be predicted based on chromosome imbalances, a ... or deletion of genes and the organization of the ... Purdue University researcher. The findings identify easily measured ... Brian Dilkes, a Purdue assistant professor of horticulture. Understanding ...
Cached Biology News:Prostate cancer's multiple personalities revealed 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 3Chromosome imbalances lead to predictable plant defects 2